Theory and practice of nicotinamide trials in pre-type 1 diabetes

Journal of Pediatric Endocrinology and Metabolism

Volumn 9, Issue 3, 1996, Pages 375-379

  Gale, Edwin A M ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; ENZYME INHIBITOR; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; RELATIVE; REVIEW;

EID: 0030036695     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.1996.9.3.375     Document Type: Review

References (18)

1. Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention: association with enhanced insulin secretion. Diabetes 1988; 37: 1574-1582.
2. Bougnères PF, Carel JC, Castano L, Boitard C, Gardin JP, Landais P, Hors J, Mihatsch MJ, Paillard M, Chaussain JL, Bach JF. Factors associated with early remission of type 1 diabetes in children treated with cyclosporine. N Engl J Med 1988; 318: 663-670.
3. American Diabetes Association. Position statement. Prevention of type 1 diabetes mellitus. Diabetes 1990; 39: 1151-1152.
4. World Health Organization Prevention of Diabetes Mellitus. Geneva: WHO, 1994, 1-98.
5. Gale EAM, Bingley PJ. Can we prevent IDDM? Diabetes Care 1994; 17: 339-344.
6. Lazarow A. Protection against alloxan diabetes. Anat Rec 1947; 97: 353-358.
7. Dulin WE, Wyse BM, Kalamazoo MS. Studies on the ability of compounds to block the diabetogenic activity of streptozotocin Diabetes 1969; 18: 459-466.
8. Yamada K, Nonaka K, Hanafusa T, Miyazaki A, Toyoshima H, Tarui S. Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis. Diabetes 1982; 31: 749-753.
9. Nomikos IN, Prowse SJ, Carotenuto P, Lafferty KJ. Combined treatment with nicotinamide and desferrioxamine prevents islet allografts destruction in NOD mice. Diabetes 1986; 35: 1302-1304.
10. Yonemura Y, Takishima T, Miwa K, Miyazadi I, Yamamota H, Okamoto H. Amelioration of diabetes mellitus in partially depancreatized rats by poly (ADP-ribose) synthetase inhibitors. Diabetes 1984; 33: 401-404.
11. Nerup J, Mandrup-Poulsen T, Molvig J, Helqvist S, Wogensen L, Egeberg J. Mechanisms of pancreatic β-cell destruction in type 1 diabetes. Diabetes Care 1990; 11 (Suppl 1): 16-23.
12. Cetkovic-Cvrlje M, Sandler S, Eizirik DL. Nicotinamide and dexamethasone inhibit IL-1 induced nitric oxide production by RINnSF cells without decreasing mRNA expression for nitric oxide synthase Endocrinology 1993; 133: 1739-1743.
13. Heller SP, Wang ZQ, Wagner EF, Radons J, Burkle A, Fehsel K, Burkart V, Kolb H. Poly(ADP-ribose) polymerase dependent and independent toxicity of oxygen radicals and nitric oxide in murine islet cells. J Biol Chem 1995; in press.
14. Elliott RB, Chase HP. Prevention or delay or type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 1991; 34: 362-365.
15. Vague P, Vialettes B, Lassman-Vague V, Vallo JJ. Nicotinamide may extend remission phase in insulin-dependent diabetes. Lancet 1987; i: 619-620.
16. Mendola G, Casamitjana R, Gomis R. Effect of nicotin-amide therapy upon B-cell function in newly-diagnosed type 1 (insulin-dependent) diabetic patients. Diabetologia 1989; 32: 160-162.
17. Vague P, Picq R, Bernal M, Lassman-Vague V, Vialettes B. Effect of nicotinamide on the residual insulin secretion of type 1 (insulin-dependent) diabetic patients. Diabetologia 1989; 32: 316-321.
18. Mandrup-Poulsen T, Reimers JI, Andersen HU, Pociot F, Karlsen AE, Bjerre U, Nerup J. Nicotinamide treatment in the prevention of insulin-dependent diabetes mellitus. Diabet/Metab Rev 1993; 9: 295-309